The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?

EuroIntervention 2014;10:21-23. DOI: 10.4244/EIJV10I1A4

1. Université de Toulouse Paul Sabatier, CHU de Toulouse, Service de Pharmacologie Clinique, Unité de Pharmacologie Cardiovasculaire et Autonome, INSERM 1048, Toulouse, France; 2. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische I
We read with interest the paper by Bhatt et al1 published in the New England Journal of Medicine. In summary, the blinded SYMPLICITY HTN-3 trial did not show a significant difference in the reduction of systolic blood pressure (BP) in patients with resistant hypertension six months after renal denervation (RDN) as compared with a sham control. The primary safety endpoint of the trial was met. Herein, we are aiming not to discuss the potential weaknesses of the trial and how these may have impacted on the results, but rather to address the question as to whether this trial is informative ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Complexities of vascular intervention for erectile dysfunction